Auh June-Sun – Chairman, Ahngook Pharm, South Korea
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
Established in 1960, CHA Health Systems (CHS) opened its first women’s medical center in Seoul, South Korea. CHS has received worldwide recognition and accolades for its excellence in clinical research and accomplishments in the fields of obstetrics and gynecology. It owns and operates, among others: Hollywood Presbyterian Medical Center, one of the largest privately-owned hospital in Los Angeles and 8 general acute-care hospital facilities throughout Korea. CHS continued its international expansion and formed CHAUM, a premier anti-aging center and 5 fertility treatment and research centers in the U.S. and Korea. The Company’s activities also include various medical and biotech ventures, including a healthcare investment firm, CHA Bio & Diostech, one of the largest biotechs listed in KOSDAQ.
CHS also introduces a premier anti-aging center, CHAUM, offering various treatments including western medicine, alternative medicine, stem-cell therapies, exercise prescription, and food therapies, targeting issues related to optimum health and wellness. It also operates a global CHAUM clinical trial center, the world’s only one-stop clinical trial center for regenerative medicine. In this center, GMP facility, surgery room, recovery room, treatment room, and in-hospitalization facility are centrally located for convenience and quality care. Its customized clinical trial services and state-of-the art facilities for the development of regenerative medicine are a major supplier to many biotech companies worldwide, which offers opportunities for small and large companies to carry out proof of concept studies and early phase clinical trials at substantial savings in time and money.
With the ultimate vision of becoming a global leader in the next generation of healthcare services, CHS continues to stay at the forefront of medical services by building its global network of hospitals/clinics and research institutes for the advancement of bio-medicine and bio-ventures.
Contact Details
Dong-kun Lee, Corporate Planning
335 Pangyo-Ro, Bundang-Gu, Seongnam City, Kyunggi-Do, Republic of Korea
Tel. (+82)31-881-7370 Cell (+82)10-9261-6160 Fax. (+82)31-881-7379
E-mail. ddkk.lee@chamc.co.kr
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
Lee Kyoung-Ryul has served as Chairman of SCL Healthcare Group since 2007. He discusses the diagnostic service providers’ extensive network in Korea as well as their ambitious plans to export…
On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry…
With a wealth of experience in different countries around the world, Christophe Piganiol came to Korea as general manager of Zuellig Pharma in 2010. Today he discusses the importance of…
Brian Wang, CEO of Korean super-generics developer GL PharmTech, discusses Korea’s relative strengths in different stages of R&D, and how this motivated the foundation and evolution of GL PharmTech. What…
Liz Chatwin came to Korea as general manager of AstraZeneca in the fall of 2013, following a period working at the company’s Chinese affiliate for several years. She contrasts the…
Lee Han-Koo, president of Daehwa Pharmaceutical, explains his strategy to corner the transdermal drug delivery system (TDDS) market through innovative patch products as well as a special focus on oral…
James Jun, CEO of KT&G Life Sciences, discusses his company’s new entry into the Korean pharma market and the role that the KT&G brand can play in accelerating its drug…
Korean success story Boryung has a goal to become the number one domestic pharmaceutical company in the coming years. The company’s CEO, Choi Tae-Hong, discusses this strategy and the victory…
Bae Byoung-Jun, director general of the Bureau of Health Industry at Korea’s Ministry of Health and Welfare, outlines the history and structure of the Korean healthcare system and highlights the…
LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth…
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
See our Cookie Privacy Policy Here
